Time is running out for Wellcome as Glaxo pounces
Wednesday 08 February 1995
The bidder's shares closed 12p lower at 649p after Glaxo admitted that sales of its largest selling drug, Zantac, the ulcer treatment, had fallen 5 per cent, with turnover in the drug's largest market, the US, hit hardest.
That kept group sales flat at £2.85bn (£2.80bn) and restricted profits growth to 10 per cent from £998m to £1.10bn. After a higher tax charge earnings per share grew 4 per cent to 24.3p and the interim dividend was 1p higher at 10.0p.
Sir Richard Sykes, deputy chairman and chief executive, said the results reflected the actions Glaxo had taken to combat the tough trading conditions facing the industry.
But Wellcome said the results compared poorly with the 18 per cent increase in earnings per share it announced last week for the year to December.
John Robb, chief executive, said: "Glaxo's results highlight its desire to acquire a company with a record of strong growth. Its offer undervalues Wellcome and we are working energetically to develop a better offer."
There was still no evidence that Wellcome had persuaded a white knight to enter the fray, although it is thought unlikely that any of the large drugs companies being touted as possible counter bidders would show their hands much before the 28 February deadline imposed by Wellcome's biggest shareholder, the Wellcome Trust.
The Trust, which holds 39.5 per cent of Wellcome, has said it will accept Glaxo's cash and shares offer, worth 1077p a share yesterday, unless a better offer emerged within 21 days of the launch of the bid.
The Manufacturing Science and Finance Union, in a letter it drafted for Wellcome employees to send to their MPs, expressed concern about the "substantial job losses" at Wellcome's manufacturing and research plants that would follow a takeover.
The MSF warned that both sites might close and said that long-term scientific research would suffer. Glaxo, the union warned, would be unable to finance the large debts it planned to take on without substantial cost-cutting throughout both companies. SirRichard said the numbers of redundancies rumoured recently were "pure speculation", but admitted that there would be closures and job losses.
Zantac sales were hit in the US by the introduction of a generic rival in anticipation of which Glaxo had to negotiate increased discounts with its biggest buyers.
- 2 Russian girl takes her own life after parents find pornography on her computer
- 4 Ball pool for adults opens in London
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Russian girl takes her own life after parents find pornography on her computer
Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
Michelle Obama highlights harsh restrictions faced by Saudi women after meeting King Salman without wearing a headscarf
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Greece elections: Syriza and EU on collision course after election win for left-wing party
Have we reached 'peak food'? Shortages loom as global production rates slow
British Muslim school children suffering a backlash of abuse following Paris attacks
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...